Solutions

Healthcare-Associated Infections Portfolio

A comprehensive suite of solutions for the screening & active infection management of HAIs and MDROs

The BD MAX™ Portfolio of HAI assays Setting higher standards in the fight against HAIs

The efficiency and versatility offered by the BD MAX™ System and the Healthcare-Associated Infections (HAIs) portfolio provides a comprehensive suite of solutions on a single, fully automated platform, enabling the laboratory to provide rapid, accurate results which can positively impact patient management.

Burden of HAIs
Consequences of HAIs
HAI detection and infection control
Healthcare-Associated Infections

Burden of HAIs

  • 4 million patients in Europe per year
    acquire an HAI1,     at a cost of an estimated €7
    billion to healthcare providers.2
  • Compounding the impact of HAIs are
    infections due to bacteria resistant to
    antimicrobials (AMR)    , many resistant to
    multiple antimicrobials (MDROs). Therefore,
    AMR is a major concern in relation to HAIs.

Consequences of HAIs

Each year, hundreds of millions of patients worldwide are affected by HAIs, or infections acquired in healthcare settings, leading to2,3

  • Significant mortality
  • Human and economic burden
  • Prolonged hospital stays
  • Long-term disability
  • Increased antimicrobial resistance

HAI detection and infection control

Early and accurate detection of HAIs combined with appropriate infection control interventions and patient treatment can:

  • Support antimicrobial stewardship initiatives
  • Prevent transmission
  • Improve patient satisfaction and life planning
  • Improve patient management

Meet the BD MAX™ Portfolio of HAI assays

The BD MAX™ Portfolio of HAI assays enables your laboratory to:

  • Provide results for up to 24 specimens in less than 3 hours
  • Decrease hands-on time for laboratory technicians versus traditional methods
  • Limit the risk of potential errors and maintain chain of custody including sample transfers and manual manipulations
  • Control total cost of ownership by limiting indirect costs

Detection of Gram Negative pathogens

BD MAX™
Check-Points CPO assay
Screening for carbapenemase-producing organism (CPO) through the identification of the five most common carbapenemase genes:
  • KPC
  • OXA-48 (OXA-48 and OXA-48 like)
  • NDM
  • VIM/IMP
Check-Points [Check-Direct]
ESBL Screen for BD MAX™4
Screening for extended-spectrum beta-lactamase (ESBL) producing pathogenic enterobacteria, can be run in parallel with BD MAX™ Check-Points CPO to detect ESBLs and carbapenemases simultaneously:
  • CTX-M-1 group
  • CTX-M-2 group
  • CTX-M-9 group
  • SHV-ESBL

Detection of Gram Positive pathogens

BD MAX™
MRSA XT
Active surveillance of methicillin- resistant Staphylococcus aureus (MRSA) with Extended Detection Technology including mecA and mecC resistance
BD MAX™
StaphSR
Differentiation of S. aureus and MRSA with the same Extended Detection Technology as the BD MAX™ MRSA XT assay
BD MAX™
Cdiff
Detection of toxigenic Clostridioides difficile through the identification of toxin B gene (tcdB)
VIASURE VanR Real
Time PCR Detection
Kit for BD MAX™
Active surveillance of vancomycin-resistant enterococci through the detection of vanA and vanB genes

The BD MAX™ System is a single platform
providing you with the versatility of running BD and partner developed assays,
as well as 3rd party and laboratory developed tests.

CPO, Carbapenemase-Producing Organism; CTX, cefotaxime-beta lactamases; ESBL, Extended-Spectrum Beta-Lactamase; HAI, Healthcare-Associated Infections; IMP, imipenemase; KPC, Klebsiella pneumoniae carbapenemase; MDRO, Multidrug-Resistant Organism; MRSA, Methicillin-Resistant Staphylococcus aureus; NDM, New Delhi metallo-β-lactamase; OXA, oxacillinase; SHV, sulphydryl variable; tcdB, toxin B gene; VIM, Verona integron-encoded metallo-β-lactamase

1. European Centre for Disease Prevention and Control. ECDC Programme on antimicrobial resistance and healthcare-associated infections. Available at: https://wiki.ecdc.europa.eu/fem/Pages/ECDC%20Programme%20on%20antimicrobial%20resistance%20and%20healthcare-associated%20infections.aspx. Accessed February 2021. 2. World Health Organization. Health care-associated infections fact sheet. Available at: https://www.who.int/gpsc/country_work/gpsc_ccisc_fact_sheet_en.pdf. Accessed February 2020. 3. World Health Organization. 2016. Health care without avoidable infections. Available at: https://apps.who.int/iris/bitstream/handle/10665/246235/WHO-HIS-SDS-2016.10-eng.pdf;jsessionid=C477D74DC9AF05C3BEA0474CF2C8B601?sequence=1. Accessed February 2020. 4. Check-Direct ESBL for BD MAX Distributed by Check-Points, info@check-points.com.

Contact us

to discuss how we can support your HAI screening needs